Filing Analysis
Cocrystal Pharma, Inc. announced the appointment of Carol L. Brosgart to its Board of Directors, effective August 12, 2026. The filing notes there are no related-party transactions or family relationships associated with this appointment.
📋 Key Facts
- Carol L. Brosgart was appointed as a director of the Company effective August 12, 2026.
- The appointment is effective immediately as of the date of the event.
- No related-party transactions or family relationships were disclosed regarding the new director.
Cocrystal Pharma, Inc. announced the appointment of Carol L. Brosgart, MD, to its Board of Directors via a press release issued on August 17, 2026.
📋 Key Facts
- Appointment of Carol L. Brosgart, MD to the Board of Directors.
- The announcement was made via a press release dated August 17, 2026.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for purposes of Section 18 liability.
Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement with OPKO Health, Inc. to issue 5,474,053 shares of common stock at $0.9134 per share. The transaction resulted in gross proceeds of $5.0 million intended for clinical drug candidate programs and working capital.
🚩 Red Flags
- Related-party transaction: Dr. Phillip Frost is the Chairman/CEO of the Purchaser (OPKO Health, Inc.) and a co-founder, director, and principal stockholder of Cocrystal Pharma, Inc.
📋 Key Facts
- Date of agreement: July 31, 2026
- Purchaser: OPKO Health, Inc.
- Shares issued: 5,474,053 shares of common stock
- Price per share: $0.9134 (based on Nasdaq Consolidated Bid Price)
- Gross proceeds: $5.0 million
- Use of proceeds: Advancement of preclinical and clinical drug candidate programs, general corporate purposes, and working capital
- Exemption: Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D
Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. The meeting resulted in the successful election of five directors and the ratification of Weinberg & Company as the independent auditor.
📋 Key Facts
- The 2026 Annual Meeting was held on July 14, 2026.
- Five individuals were elected to the Board of Directors: Dr. Roger Kornberg, Dr. Phillip Frost, Mr. Fred Hassan, Mr. Richard C. Pfenniger, Jr., and Mr. Steven Rubin.
- Weinberg & Company was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (adjournment of meeting) was rendered moot as sufficient votes were obtained for Proposals 1 and 2.
Cocrystal Pharma appointed James Sapirstein as Chief Executive Officer effective June 3, 2026. He replaces the previous Co-CEO structure consisting of Sam Lee and James Martin.
🚩 Red Flags
- Shift from a Co-CEO leadership structure to a single CEO often indicates a strategic pivot or a need for centralized decision-making following previous instability or lack of progress.
📋 Key Facts
- James Sapirstein appointed as CEO on June 3, 2026.
- Compensation includes a base salary of $265,000 and a performance bonus of 50% of base salary.
- Initial equity grant of 10-year stock options for 235,000 shares at an exercise price of $1.05.
- Potential for an additional grant of 235,000 options on the six-month anniversary of start date, subject to performance and committee approval.
- Mr. Sapirstein previously served as CEO of Entero Therapeutics, Inc. (Nasdaq: ENTO) from 2019 to 2025.
- Former Co-CEOs Sam Lee and James Martin transition to President/CSO and CFO roles, respectively.
Cocrystal Pharma, Inc. announced the appointment of James Sapirstein as the company's new Chief Executive Officer on June 3, 2026.
📋 Key Facts
- James Sapirstein appointed as Chief Executive Officer
- Announcement made via press release on June 3, 2026
- Filing signed by James Martin, Chief Financial Officer
Cocrystal Pharma, Inc. (COCP) filed an 8-K to furnish a press release dated May 26, 2026, regarding its novel direct-acting antivirals.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- The subject of the press release is the company's novel direct-acting antivirals.
- The press release is attached as Exhibit 99.1.
Cocrystal Pharma announced that its oral protease inhibitor, CDI-988, was featured in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026). The presentation focused on the drug's mechanism of action and its current clinical advancement.
📋 Key Facts
- Oral presentation at ICAR 2026 in Prague, Czech Republic on April 30, 2026.
- Featured drug candidate: CDI-988, an oral protease inhibitor.
- Presentation covered mechanism of action and clinical progress.
Cocrystal Pharma announced that the FDA has granted Fast Track designation to its oral antiviral candidate, CDI-988, for the treatment and prophylaxis of norovirus infection. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs.
📋 Key Facts
- FDA granted Fast Track designation to CDI-988 on April 2, 2026.
- CDI-988 is an oral, direct-acting protease inhibitor candidate.
- The drug is being developed for both treatment and prophylaxis of norovirus infection.
- The company claims CDI-988 is the first oral antiviral candidate for this specific indication.
Cocrystal Pharma, Inc. (COCP) filed an 8-K to announce its financial results for the fiscal year ended December 31, 2025. The filing includes a press release with business updates and financial performance metrics.
🚩 Red Flags
- Clerical inconsistency: The body text of Item 2.02 incorrectly states the press release was issued on November 14, 2025, for the fiscal year ended December 31, 2025, which is chronologically impossible.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The press release (Exhibit 99.1) is dated March 31, 2026.
- The report was signed by James Martin, who holds the dual role of Co-Chief Executive Officer and Chief Financial Officer.
- The filing includes a clerical error in the Item 2.02 text, which incorrectly references a November 14, 2025 date for the year-end results announcement.
Cocrystal Pharma, Inc. reported the passing of Dr. Anthony Japour, a member of the company's Board of Directors, on March 10, 2026.
📋 Key Facts
- The company was notified of Dr. Anthony Japour's death on March 10, 2026.
- Dr. Japour served as a member of the Board of Directors.
- The filing was made under Item 5.02 of Form 8-K.
Cocrystal Pharma, Inc. issued a press release on March 9, 2026, providing a clinical update on its Phase 1b norovirus challenge study. The study is evaluating the drug candidate CDI-988 for its efficacy as both a preventive and treatment for norovirus infections.
📋 Key Facts
- The filing was made under Item 7.01 Regulation FD Disclosure on March 9, 2026.
- The update concerns the Phase 1b norovirus challenge study for drug candidate CDI-988.
- CDI-988 is being developed as both a preventive and a treatment for norovirus.
- The report was signed by James Martin, who serves as both Co-Chief Executive Officer and Chief Financial Officer.
Cocrystal Pharma disclosed via Regulation FD that its oral norovirus protease inhibitor CDI-988 will be featured at the International Society for Antiviral Research Conference (ICAR) 2026 in Prague, April 27–May 1, 2026. This is a routine scientific conference presentation announcement with no material financial or structural changes to the company.
🚩 Red Flags
- James Martin holds dual role as Co-CEO and CFO, concentrating executive authority
- Reg FD disclosure is 'furnished' not 'filed,' offering limited investor protection
📋 Key Facts
- CDI-988 is described as the Company's 'first oral norovirus protease inhibitor'
- Drug candidate will be featured at ICAR 2026, held April 27–May 1, 2026 in Prague, Czech Republic
- Filing signed by James Martin, Co-Chief Executive Officer and Chief Financial Officer (dual role)
- Company is incorporated in Delaware, headquartered in Bothell, WA
- Trades on Nasdaq Capital Market under ticker COCP
- Information furnished under Item 7.01 (not 'filed'), limiting liability exposure
Cocrystal Pharma, Inc. announced the approval of non-qualified stock option grants to various directors, executive officers, and a consultant under its 2025 Equity Incentive Plan. The filing also notes a $50,000 cash award for Dr. Roger Kornberg for his service as Chairman of the Scientific Advisory Board.
🚩 Red Flags
- Related-party transaction: $50,000 cash award to Dr. Roger Kornberg (Chairman of the Scientific Advisory Board)
📋 Key Facts
- Grant date: January 9, 2026
- Options exercisable at the closing price of January 8, 2026
- Vesting schedule: 50% on Jan 9, 2027; remaining 50% in eight equal quarterly installments starting March 31, 2027
- James Martin (CEO/CFO) and Sam Lee were granted 49,229 stock options each
- Dr. Roger Kornberg received a $50,000 cash award for Scientific Advisory Board service
Cocrystal Pharma, Inc. announced that the Institutional Review Board (IRB) at Emory University School of Medicine has approved a Phase 1b human challenge study for its candidate CDI-988. The study is designed to evaluate CDI-988's efficacy as both a preventive and treatment measure for norovirus infections.
📋 Key Facts
- IRB approval received from Emory University School of Medicine on December 18, 2025.
- Initiation of Phase 1b human challenge study for CDI-988.
- Study objective: Evaluate CDI-988 as a preventive and treatment for norovirus infections.
Cocrystal Pharma, Inc. announced that its Co-CEO and CFO, James Martin, will present a company overview and clinical progress update at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 3, 2025.
📋 Key Facts
- James Martin (Co-CEO and CFO) to present at Noble Capital Markets conference.
- Presentation date: Wednesday, December 3, 2025, at 10:00am ET.
- Content includes company overview and clinical progress updates.
Cocrystal Pharma, Inc. filed an 8-K to announce its quarterly results of operations for the fiscal quarter ended September 30, 2025 and provided general business updates.
📋 Key Facts
- Report date: November 14, 2025
- Period covered: Fiscal quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results and business updates.
- Signed by James Martin, Co-CEO and CFO.
Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement on October 28, 2025, to raise $1.03 million through the sale of units to four insider investors. The offering includes common stock and warrants with an exercise price below the current unit purchase price.
🚩 Red Flags
- Related-party transaction: The purchasers are identified as 'four insiders of the Company'
- Dilutive structure: Warrants issued at $1.24, which is below the current unit price of $1.39
- Small capital raise: Total proceeds of $1.03 million suggest limited runway/liquidity needs
- No registration rights provided to purchasers
📋 Key Facts
- Date of agreement: October 28, 2025
- Total gross proceeds: $1.03 million
- Units sold: 739,426 units at $1.39 per unit
- Unit composition: One share of common stock and one warrant to purchase two shares of common stock
- Warrant terms: Exercise price of $1.24 per share; 27-month term
- Purchasers: Four insiders of the Company (accredited investors)
Cocrystal Pharma, Inc. announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I award from the NIH and NIAID.
📋 Key Facts
- Awarded an SBIR Phase I grant by the National Institutes of Health (NIH).
- Grant issued specifically through the National Institute of Allergy and Infectious Diseases (NIAID).
- The announcement was made via press release on October 27, 2025.
Cocrystal Pharma, Inc. completed a registered direct offering and concurrent private placement of warrants, raising approximately $4.75 million in gross proceeds. The offering includes significant warrant coverage that will lead to future dilution.
🚩 Red Flags
- Significant dilution risk: The number of warrants (5.5M) exceeds the number of common shares issued in the offering (2.76M).
- Warrant exercise price ($1.50) is below the offering price ($1.70), creating immediate downward pressure.
- Liquidated damages clause: The company must pay cash if it fails to deliver shares upon warrant exercise within the prescribed period.
- High cost of capital: Total fees and warrants issued to the placement agent represent significant equity/cash leakage.
📋 Key Facts
- Registered Direct Offering: 2,764,710 shares at $1.70 per share.
- Private Placement Warrants: Up to 5,529,420 warrants with an exercise price of $1.50 per share.
- Gross proceeds from the offering totaled approximately $4.75 million as of September 15, 2025.
- Placement Agent (H.C. Wainwright & Co., LLC) received a 7.0% cash fee and a 1.0% management fee, plus warrants for 207,353 shares at $2.125 per share.
- The company is required to file an S-1 registration statement by October 10, 2025, for the resale of warrant shares.
Cocrystal Pharma, Inc. issued an 8-K to furnish a press release regarding a presentation by President and co-CEO Dr. Sam Lee at the 9th International Calicivirus Conference.
📋 Key Facts
- The filing is under Item 7.01 (Regulation FD Disclosure).
- Dr. Sam Lee, PhD (President and co-CEO) discussed the CDI-988 product candidate.
- The presentation occurred at the 9th International Calicivirus Conference in Banff, Alberta, held September 7–11, 2025.
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Cocrystal Pharma, Inc. has announced the pricing of a registered direct offering of common stock alongside a concurrent private placement of warrants. This type of financing is typically used by micro-cap biotech companies to raise immediate working capital.
🚩 Red Flags
- Dilutive event: Registered direct offerings and warrant issuances typically result in significant dilution for existing shareholders.
- Micro-cap financing pattern: Frequent use of registered direct offerings often indicates a need for immediate liquidity to fund operations (burn rate management).
📋 Key Facts
- Date of report: September 12, 2025
- The company issued a registered direct offering of common stock.
- A concurrent private placement of warrants was announced.
- Pricing for the offering and warrants has been finalized as of the filing date.
Cocrystal Pharma, Inc. announced its results of operations for the fiscal quarter ended June 30, 2025. The filing serves as a formal notice that a press release containing these financial results was issued on August 14, 2025.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2025.
- Filing date: August 14, 2025.
- The company furnished a press release (Exhibit 99.1) regarding its financial condition and operations.
Cocrystal Pharma, Inc. issued a press release regarding the presentation of Phase 1 clinical study data for its pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium.
📋 Key Facts
- Company presented safety and tolerability data from a randomized, double-blinded, placebo-controlled Phase 1 study.
- The drug candidate is an oral, direct-acting pan-viral inhibitor named CDI-988.
- Data was presented at the 2025 Military Health System Research Symposium (MHSRS) held August 4-7, 2025.
- Filing includes a press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2).
Cocrystal Pharma, Inc. issued an 8-K to announce that its broad-spectrum protease inhibitor, CDI-988, will be featured in an oral presentation at the upcoming 9th International Calicivirus Conference.
📋 Key Facts
- Company is announcing a scientific presentation regarding CDI-988.
- The presentation will take place at the 9th International Calicivirus Conference.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
Cocrystal Pharma, Inc. held its 2025 Annual Meeting of Stockholders on June 25, 2025. The meeting resulted in the successful election of six directors and the ratification of the company's independent auditor.
📋 Key Facts
- The 2025 Annual Meeting was held on June 25, 2025.
- Six individuals were elected to the Board of Directors: Dr. Roger Kornberg, Dr. Phillip Frost, Mr. Fred Hassan, Dr. Anthony Japour, Mr. Richard C. Pfenniger, Jr., and Mr. Steven Rubin.
- Stockholders ratified the appointment of Weinberg & Company as the independent registered public accounting firm for fiscal year 2025.
- The 2025 Equity Incentive Plan was approved by stockholders.
- Proposal 4 (adjournment to permit further solicitation) was rendered moot because sufficient votes were obtained for Proposals 1-3.
Cocrystal Pharma, Inc. has amended its bylaws to change the quorum requirement for stockholder meetings. The amendment specifies that one third of the aggregate voting power of outstanding shares constitutes a quorum.
🚩 Red Flags
- Lowering quorum requirements can sometimes be used by management to facilitate corporate actions with lower shareholder participation, though it is a common administrative adjustment.
📋 Key Facts
- Board approval date: June 17, 2025
- Amendment type: Amendment No. 1 to Amended and Restated Bylaws
- New Quorum Requirement: One third (33.3%) of the aggregate voting power of outstanding shares entitled to vote.
- Effective Date: Approved June 17, 2025.
Cocrystal Pharma, Inc. issued an 8-K to provide Regulation FD disclosure regarding a press release. The company announced that its protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium.
📋 Key Facts
- Company is announcing an upcoming oral presentation for its broad-spectrum protease inhibitor, CDI-988.
- The presentation will take place at the 2025 Military Health System Research Symposium.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The information is provided via a press release dated June 5, 2025.
Cocrystal Pharma, Inc. issued an 8-K to furnish a press release regarding clinical/developmental updates for its novel broad-spectrum influenza PB2 inhibitor.
📋 Key Facts
- The filing is a Regulation FD disclosure (Item 7.01) providing an update on the company's influenza PB2 inhibitor program.
- The report was filed on May 29, 2025.
- The information provided in Exhibit 99.1 is not considered 'filed' for purposes of Section 18 liability.
Cocrystal Pharma, Inc. filed an 8-K to announce its results of operations for the fiscal quarter ended March 31, 2025. The filing serves as a formal notification that a press release containing these financial results has been issued.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The filing includes Exhibit 99.1 (Press Release) regarding results of operations.
- Signed by James Martin, CFO and Co-CEO.
Cocrystal Pharma, Inc. issued an 8-K to furnish a press release regarding its norovirus oral antiviral candidate. This is a non-binding disclosure under Regulation FD.
📋 Key Facts
- Filed on April 24, 2025
- The filing pertains to the company's norovirus oral antiviral candidate
- Information was released via press release (Exhibit 99.1)
- Disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure)
Cocrystal Pharma, Inc. filed an 8-K to disclose a corporate presentation made to members of the investment community on April 23, 2025.
📋 Key Facts
- The company held a presentation for the investment community on April 23, 2025.
- A copy of the slide presentation was furnished as Exhibit 99.1.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
Cocrystal Pharma, Inc. announced that its Board of Directors approved the 2025 Equity Incentive Plan, effective March 31, 2025. The plan is subject to shareholder approval and aims to incentivize employees, officers, and directors through various equity-based awards.
📋 Key Facts
- The 2025 Equity Incentive Plan was approved by the Board on April 2, 2025, with an effective date of March 31, 2025.
- Initial authorization is for up to 1,500,000 shares of common stock.
- The plan includes an automatic annual increase of 5% of the total outstanding common stock on January 1st, starting in 2026, capped at a total of 4,000,000 shares.
- Eligible participants include employees, consultants, officers, and directors.
- Available award types: restricted stock, RSUs, options, and Stock Appreciation Rights (SARs).
- The plan is subject to shareholder approval at the next meeting.
Cocrystal Pharma, Inc. filed this 8-K to provide a corrected auditor's consent from Weinberg & Company. The correction is necessary because the previous version omitted a reference to the company's effective registration statement on Form S-3.
📋 Key Facts
- Filing date: April 1, 2025
- Report date: March 31, 2025
- Purpose: To file a corrected version of the auditor's consent originally included as Exhibit 23.1 to the FY2024 Form 10-K.
- Correction details: The original consent omitted a reference to the Company’s effective registration statement on Form S-3 (No. 333-271883).
- Auditor involved: Weinberg & Company.
Cocrystal Pharma, Inc. filed an 8-K to announce its results of operations for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's annual financial performance via an attached press release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Cocrystal Pharma, Inc. filed an 8-K to furnish a corporate presentation being delivered to members of the investment community on January 13, 2025.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- A corporate presentation dated January 13, 2025, was furnished as Exhibit 99.1.
- The information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
Cocrystal Pharma, Inc. issued a press release announcing favorable interim topline Phase 1 study results for its oral pan-viral protease inhibitor, CDI-988, targeting norovirus and coronavirus infections.
📋 Key Facts
- Announcement date: January 8, 2025
- Subject: Interim topline Phase 1 study results for CDI-988
- Indication: Treatment of norovirus and coronavirus infections
- Mechanism: Oral Pan-Viral Protease Inhibitor
Cocrystal Pharma, Inc. issued a press release announcing the extension of enrollment for its Phase 2a human challenge study involving the oral influenza PB2 inhibitor CDI-42344.
📋 Key Facts
- Announcement date: December 31, 2024
- Subject: Extension of enrollment in Phase 2a human challenge study
- Drug candidate: CDI-42344 (broad-spectrum, oral influenza PB2 inhibitor)
Cocrystal Pharma, Inc. filed an 8-K to furnish its results of operations for the fiscal quarter ended September 30, 2024 via a press release.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information is furnished but not 'filed' for purposes of Section 18 liability
Cocrystal Pharma, Inc. filed an 8-K to furnish a press release regarding its antiviral product candidates and their target viruses. The filing does not contain material financial changes or structural corporate updates.
📋 Key Facts
- Filed on October 31, 2024
- The company issued a press release concerning certain antiviral product candidates (Exhibit 99.1)
- The disclosure pertains to the viruses targeted by these specific candidates
Cocrystal Pharma, Inc. announced that its Board of Directors ratified compensation increases for executive officers and approved various cash stipends and RSU grants for non-employee directors, effective August 12, 2024.
🚩 Red Flags
- Ratification of past compensation (effective August 12) rather than prospective approval can sometimes indicate administrative oversight or late reporting.
📋 Key Facts
- Executive officers James Martin (CFO/Co-CEO) and Dr. Sam Lee (President/Co-CEO) received base salary increases from $400,000 to $416,000.
- Each executive officer was awarded a $200,000 bonus and 40,000 Restricted Stock Units (RSUs).
- Non-employee directors were granted various cash stipends ranging from $36,300 to $100,000.
- RSU grants for directors include vesting schedules: 50% vests immediately, and 50% vests in eight equal quarterly installments starting September 30, 2025.
- The Board ratified these actions effective as of August 12, 2024.
Cocrystal Pharma, Inc. filed an 8-K to announce its participation in upcoming investment conferences via a press release.
📋 Key Facts
- The company issued a press release on August 19, 2024, regarding conference participation.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Chief Financial Officer and Co-CEO James Martin signed the report.
Cocrystal Pharma, Inc. filed an 8-K to furnish its results of operations for the fiscal quarter ended June 30, 2024. The filing serves as a formal announcement of quarterly financial performance via a press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024.
- Filing date: August 14, 2024.
- The filing includes Exhibit 99.1 containing the official press release of results.
Cocrystal Pharma, Inc. issued a press release regarding clinical development updates for its CDI-988 candidate. The update specifically covers single-ascending dose cohorts from the Phase 1 study targeting coronaviruses and noroviruses.
📋 Key Facts
- Company released clinical development updates on July 18, 2024.
- Updates pertain to the Phase 1 study of CDI-988 candidate.
- Study focus: single-ascending dose cohorts for antiviral treatment of coronaviruses and noroviruses.
Cocrystal Pharma, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 25, 2024. The meeting resulted in the election of six directors and the approval of an amendment to reduce authorized capital stock.
🚩 Red Flags
- Shareholders rejected Proposal 4, which sought to limit the liability of the Company's officers; this indicates potential investor dissatisfaction with current governance/liability protections.
📋 Key Facts
- Stockholders approved a reduction in authorized capital stock from 155,000,000 shares (150M common/5M preferred) to 101,000,000 shares (100M common/1M preferred), effective June 27, 2024.
- Six directors were elected: Roger Kornberg, Phillip Frost, Fred Hassan, Anthony Japour, Richard C. Pfenniger, Jr., and Steven Rubin.
- Weinberg & Company was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- A proposal to limit the liability of the Company's officers (Proposal 4) was NOT approved by stockholders.
- Stockholders approved a voting frequency for executive compensation every three years.
Cocrystal Pharma, Inc. issued an 8-K to furnish a press release regarding a clinical/product update for its CC-42344 antiviral candidate targeting influenza A.
📋 Key Facts
- The filing is a Regulation FD disclosure (Item 7.01) providing an update on the CC-42344 product candidate.
- CC-42344 is being developed as a potential treatment for pandemic and seasonal influenza A.
- The report was filed on June 20, 2024.
Cocrystal Pharma, Inc. filed an 8-K to furnish its quarterly results of operations for the fiscal quarter ended March 31, 2024 and provided updates on its antiviral drug development programs.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Fiscal quarter ended March 31, 2024
- Content includes results of operations and updates on antiviral drug development programs
- The information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability
Cocrystal Pharma, Inc. issued a press release regarding clinical development updates for its CC-42344 candidate, intended as an antiviral treatment for influenza A.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- The company provided updates on the clinical development of CC-42344.
- CC-42344 is being developed as a potential antiviral treatment for pandemic and seasonal influenza A.
- The report was filed on May 1, 2024.
Cocrystal Pharma, Inc. filed an 8-K to furnish its results of operations for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of their annual financial performance via a press release.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the full press release of results.
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
Cocrystal Pharma, Inc. issued a press release regarding clinical development updates for its CDI-42344 compound, intended to treat and prevent influenza A.
📋 Key Facts
- The filing relates to clinical development updates for the CDI-42344 compound.
- CDI-42344 is being developed as a potential treatment and prophylaxis for influenza A.
- The update was issued via press release on March 19, 2024.
Cocrystal Pharma, Inc. has elected to terminate two License Agreements with the Kansas State University Research Foundation effective March 29, 2024. The company stated the termination is due to a determination that further development efforts under these specific agreements would be futile.
🚩 Red Flags
- Termination of research/license agreements due to 'futility' suggests a failure in the development pipeline related to those specific assets.
- Potential loss of intellectual property rights or collaborative research momentum associated with the Kansas State University Research Foundation agreements.
📋 Key Facts
- Termination of License Agreements dated February 12, 2020, and April 19, 2020.
- Effective date of termination: March 29, 2024.
- Reason for termination: Company determined further development efforts under the agreements would be futile.
- The company's proprietary compound CDI-988 (pan-viral therapeutic) is not affected by this termination and remains in Phase 1 clinical trials.
Cocrystal Pharma, Inc. filed an 8-K to furnish a corporate presentation being delivered to members of the investment community on January 8, 2024.
📋 Key Facts
- The company is making a presentation to certain members of the investment community on January 8, 2024.
- A copy of the slide presentation is provided as Exhibit 99.1.
- Information under Item 7.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cocrystal Pharma, Inc. issued a press release providing clinical development updates for its CDI-988 (norovirus/coronavirus) and CC-42344 (influenza A) product candidates.
📋 Key Facts
- Filed on January 4, 2024.
- Updates provided regarding CDI-988 clinical development for norovirus and coronavirus treatments.
- Updates provided regarding CC-42344 clinical development for pandemic and seasonal influenza A treatments.